Table 1 Demographic information, clinical manifestations, SLEDAI scores, and neuropsychiatric disorders among all study patients and subgroups
All patients (n = 90) | AQP4-IgG Ab negative subgroup (n = 34) | AQP4-IgG Ab positive subgroup (n = 56) | Test of significance | |
|---|---|---|---|---|
Age/years | 14.46 ± 2.75 | 14.06 ± 2.93 | 14.69 ± 2.62 | p = 0.289 |
Sex | ||||
Male (%) | 7.8 | 11.8 | 5.4 | P = 0.419 |
Female (%) | 92.2 | 88.2 | 94.6 | |
New patients (%) | 26.7 | 35.3 | 21.4 | p = 0.149 |
BMI kg/m2 | 25.23 ± 4.33 | 24.72 ± 4.49 | 25.54 ± 4.24 | p = 0.385 |
SLEDAI score | ||||
Mild (%) | 30.0 | 52.9 | 16.1 | |
Moderate (%) | 25.6 | 32.4 | 21.4 | p < 0.001* |
High (%) | 32.2 | 14.7 | 42.9 | |
Very high (%) | 12.2 | 0 | 19.6 | |
Mood disorders (%) | 57.8 | 50 | 62.5 | p = 0.244 |
Psychosis (%) | 50 | 32.4 | 60.7 | p = 0.009* |
Headache (%) | 47.8 | 35.3 | 55.4 | p = 0.065 |
Anxiety (%) | 47.8 | 35.3 | 55.4 | p = 0.065 |
Seizures (%) | 31.1 | 17.6 | 39.3 | p = 0.032* |
CVD (%) | 26.7 | 20.6 | 30.4 | p = 0.310 |
Polyneuropathy (%) | 17.8 | 14.7 | 19.6 | p = 0.553 |
Acute confusional state (%) | 12.2 | 5.9 | 16.1 | p = 0.152 |
Movement disorder (%) | 10 | 5.9 | 12.5 | p = 0.310 |
Cranial neuropathy (%) | 10 | 2.9 | 14.3 | p = 0.082 |
Cognitive dysfunction (%) | 8.9 | 2.9 | 12.4 | p = 0.122 |
Aseptic meningitis (%) | 7.8 | 2.9 | 10.7 | p = 0.182 |
Autonomic neuropathy (%) | 5.6 | 5.9 | 5.4 | P = 1.0 |
Myelopathy (%) | 4.4 | 2.9 | 5.4 | P = 1.0 |
Demyelination (%) | 1.1 | 0 | 2.9 | P = 0.378 |
Myasthenia gravis (%) | 1.1 | 0 | 2.9 | P = 0.378 |